Cosmo Public Relations
Advertising Networks · Japan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1-8-10 Azabudai 7F, Tokyo, Tokyo, 106-00...Phone Number
+81 355612911Website
www.cosmopr.co.jpRevenue
$9.1 MillionIndustry
About Cosmo Public Relations
Cosmo Public Relations Org Chart
Is Cosmo Public Relations your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cosmo Public Relations launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cosmo Public Relations recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cosmo Public Relations
Click to see if Cosmo Public Relations had a recent Job posting/layoffs
Cosmo Public Relations, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cosmo Public Relations has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cosmo Public Relations has new funding data
Check out if Cosmo Public Relations is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Cosmo Public Relations as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Cosmo Public Relations is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cosmo Public Relations is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cosmo Public Relations.
Cosmo Public Relations Tech Stack
A closer look at the technologies used by Cosmo Public Relations
Cosmo Public Relations News & Media
Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
LYON, France & OSAKA, Japan--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516, hereinafter called “Poxel”), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, and Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada; Securities Code: 4506, First Section of TSE, hereinafter called “Sumitomo Dainippon Pharma”), announced today the initiation
Top Advertising Networks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cosmo Public Relations
COSMO PR is one of Japan's leading independent strategic communication consultancies, specializing in professional communication services for the healthcare sector. The company offers a full range of services from planning to execution, including healthcare communication and content design. With extensive experience and a network of key opinion lea... Read More